Stockscreener 앱 받기
0.3798
1.00%
0.00377
전일 마감가:
$0.376
열려 있는:
$0.371
하루 거래량:
263.53K
Relative Volume:
1.26
시가총액:
$8.70M
수익:
$81.89M
순이익/손실:
$-55.20M
주가수익비율:
-0.1409
EPS:
-2.6959
순현금흐름:
$-67.40M
1주 성능:
-5.05%
1개월 성능:
-1.53%
6개월 성능:
-25.53%
1년 성능:
-86.95%
1일 변동 폭
$0.341
$0.40
1주일 범위
$0.341
$0.4199
52주 변동 폭
$0.341
$3.8782
Turnstone Biologics Corp Stock (TSBX) Company Profile
명칭
Turnstone Biologics Corp
전화
347-897-5988
주소
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
TSBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.3798 | 8.70M | 81.89M | -55.20M | -67.40M | -2.6959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-11-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-10-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-08-16 | 개시 | SVB Securities | Market Perform |
| 2023-08-15 | 개시 | BofA Securities | Buy |
| 2023-08-15 | 개시 | Piper Sandler | Overweight |
모두보기
Turnstone Biologics Corp 주식(TSBX)의 최신 뉴스
Analysts Set Expectations for TSBX Q1 Earnings - Defense World
Turnstone Biologics Corp: Strategic Partnerships and Financial Position Justify Hold Rating - TipRanks
Turnstone Biologics Reports 2024 Financial Results - TipRanks
Turnstone Biologics moves to Nasdaq Capital Market By Investing.com - Investing.com South Africa
Turnstone Biologics moves to Nasdaq Capital Market - Investing.com
Turnstone Biologics Corp. SEC 10-K Report - TradingView
Turnstone Biologics Cuts Losses by $3.6M as Company Pivots Strategy - Stock Titan
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Growth in Short Interest - Defense World
Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.35 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.35 - Investing.com India
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Large Drop in Short Interest - Defense World
Turnstone Biologics Stock Hits 52-Week Low at $0.36 Amid Challenges - Investing.com Australia
Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada
Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks
Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter
Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World
A Look at Turnstone Biologics Corp (TSBX) Shares in the Recent Past Indicates Growth - SETE News
TSBX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Turnstone Biologics to explore strategic alternatives - The Pharma Letter
Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75 - Marketscreener.com
Turnstone Biologics Corp (NASDAQ: TSBX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Piper Sandler cuts Turnstone Biologics stock rating to neutral - MSN
Turnstone Biologics halts TIDAL-01 development, seeks alternatives By Investing.com - Investing.com South Africa
Ottawa-born Turnstone Biologics halting clinical studies, laying off staff - Ottawa Business Journal
TSBX’s price-to-book ratio: An indicator of the company’s performance - US Post News
Turnstone Biologics Stops Tidal-01 Trials, Explores Strategic Alternatives; Shares Rise - Marketscreener.com
Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes - TipRanks
Turnstone Biologics Announces Plans to Explore Strategic Alternatives - The Manila Times
Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review - Nasdaq
Scailyte Announces Collaboration With Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors With TIL Therapy - ACCESS Newswire
Head to Head Survey: Turnstone Biologics (NASDAQ:TSBX) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Reviewing AlloVir (NASDAQ:ALVR) and Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics (NASDAQ:TSBX) Stock Price Down 9.1% – Time to Sell? - Defense World
Fmr LLC Boosts Stock Position in Turnstone Biologics Corp. (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.44 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.44 - Investing.com
Turnstone Biologics Corp (TSBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):